Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Epitope Suppliers In Europe
44 companies found
Premium
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
Enables long term cell storage at -80°C or -196°C. Improved cell recovery and viability after thawing. Ready-to-use freezing media – no programmed or sequential freezing required. Serum-free – no risk of contamination. GMP ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inMoers, GERMANY
MEDIWISS Analytic GmbH has been developing, manufacturing and selling their own medical products since the foundation in 1999 in Moers, Germany. Our experience in allergologic in vitro diagnostics, developments and technologies has transformed us ...
based inGhent, BELGIUM
ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Our lead candidate XVR011 is in accelerated development as a COVID-19 ...
XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. ...
based inMölndal, SWEDEN
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on ...
ALZ-201 is a monoclonal antibody that is specific for the toxic Aβ oligomers. ALZ 201 is currently in early preclinical ...
based inVienna, AUSTRIA
We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
Creative Biolabs provides a comprehensive range of services based on our matured platform, which involves in the custom antibody development service, from antigen design and epitope prediction to antibody purification and labeling. ...
based inAalborg Øst, DENMARK
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP platform. To develop novel, cost ...
2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inCAEN, FRANCE
Lys Therapeutics, first-in-class biotherapies against neurological diseases. Lys Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from neurovascular or neurodegenerative disorders, including stroke and ...
Glunomab / Glunozumab®: a monoclonal antibody counteracting the strong toxicity triggered by the interaction of an endogenous protease, tissue plasminogen activator (tPA) with NMDA receptors ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of ...
based inKraków, POLAND
Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced ...
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
ProM2® MHC Class II Monomers, biotinylated enabling specialist assays for defined MHC Class II peptide target interactions. Best in class MHC Class II Monomers: ProM2® Class II MHC Monomers are pre-biotinylated and can be readily adapted ...
based inMartinsried, GERMANY
Proteros is a Munich-based provider of structure-based early stage drug discovery services with a cutting-edge discovery engine tailored to unlock even the most technically challenging drug targets. Proteros supports its clients to reach the right ...
based inHennigsdorf, GERMANY
We are a biotechnology company, located with our headquarters in Hennigsdorf just outside Berlin and our production site in Berlin-Buch. Directions can be found here. We provide our customers with a range of products in the field of protein array ...
based inCrumlin, UNITED KINGDOM
BBI Solutions offer a portfolio of products and services that are delivered to the diagnostic and life science industries globally. BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest ...
Abbreviations: hCG; Preservatives: 0.1% NaN3; Storage: Must be stored at 2°C to 8°C; Manufacturer Country: USA; Buffer: 0.15M PBS; Disease Area: Hormones; Purity/grade: determined by Size Exclusion Chromatography; Applications: EIA, Western ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
Scancell’s lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from ...
based inMons, BELGIUM
D-tek s.a. is a private Belgian biotechnology company created in 1995 in Mons (40 km from Brussels and less than 1h20 from Paris). The company is located in 1.200 square meters facilities in the Scientific Park Initialis of Mons. The company is ...
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease ...
based inWendelsheim, GERMANY
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound ...
The misfolding/ aggregation pathway resulting in amyloid fibrils involves characteristic oligomer species which have been shown to be the most relevant toxic protein species. These pathological oligomers exhibit structural epitopes ...
based inSan Diego, CALIFORNIA (USA)
BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality ...